Intrahepatic cholestasis of pregnancy

Geenes, Victoria; Williamson, Catherine; Chappell, Lucy C

doi:10.1111/tog.12308

Cited by 39 publications

(52 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…An elevated serum bile acid and transaminase concentration is also required for diagnosis [1]. In Europe, the incidence of ICP is approximately 1%, but rates vary geographically [2]. In Finland, the incidence is approximately 1.0−1.5% [3] and in Sweden the incidence is 0.5−0.75% [4].…”

Section: Introductionmentioning

confidence: 99%

Intrahepatic Cholestasis of Pregnancy and Cancer: A Cohort Study

Hamalainen¹,

Turunen²,

Mattila³

et al. 2017

Fam Med Med Sci Res

View full text Add to dashboard Cite

Objective: In a previous questionnaire study, more breast cancers were reported by women with intrahepatic cholestasis of pregnancy (ICP) than by the controls. The aim of this study was to establish whether ICP is associated with cancer in the Finnish Cancer Registry data, the study population being the same cohort as in the questionnaire study. Methods:The study population comprised 571 women with ICP in at least one pregnancy and 1,333 controls from Tampere University Hospital in Finland during [1969][1970][1971][1972][1973][1974][1975][1976][1977][1978][1979][1980][1981][1982][1983][1984][1985][1986][1987][1988]. The cancer data were obtained from the Finnish Cancer Registry. The cancers were classified by ICD-O-3 and diagnosed during the period 1953−2013. Results:In the ICP group, the odds ratio of cancers (OR 1.26, 95% CI 0.96-1.64), and breast cancer in particular (OR 1.36, 95% CI 0.91-2.03), was slightly higher than in the control group. Seven percent of the ICP group and 5.3% of the control group had breast cancer. Conclusion:Based on this study there is not a significant association between ICP and cancer. Earlier observation in the questionnaire study regarding association between ICP and breast cancer cannot be confirmed by this registry based study.

show abstract

Section: Introductionmentioning

confidence: 99%

Intrahepatic Cholestasis of Pregnancy and Cancer: A Cohort Study

Hamalainen¹,

Turunen²,

Mattila³

et al. 2017

Fam Med Med Sci Res

View full text Add to dashboard Cite

show abstract

“…ICP develops during second half to third trimester of pregnancy. In the first description of ICP in 1883, Ahlfield described maternal pruritus and jaundice 2 in the last trimester of pregnancy disappearing after delivery. A low incidence of 0.2% in Europe and a high incidence of 14% in Chile have been reported.…”

Section: Introductionmentioning

confidence: 99%

Maternal and Foetal outcome in Cholestasis of Pregnancy

Sinha

Pandey

Das

2017

J. Nepalgunj Med. College

View full text Add to dashboard Cite

Background: Obstetric cholestasis has been associated with an increased risk of preterm delivery, intrapartum meconium, foetal distress and intrauterine foetal death. Objectives: To know the perinatal outcome of cholestasis in pregnancy. Materials & Methods: This is a hospital based Observational study conducted in the department of Obstetrics & Gynaecology at Nepalgunj Medical College Teaching Hospital Kohalpur between August 2015 to January 2016.A total of 40 patients were included in the study with diagnosis of obstetric cholestasis. Data were recorded & analysed. Results: The study group of 40 mothers delivered 40 new born. Mean age group of women in the study was 24.9±5.5 years & 70% were primigravida. The mean gestational age at onset of pruritus was 30.33±4.24 weeks. The rate of caesarean section was 40%. Premature membrane rupture noted in 20% cases while 17.5% were postpartum haemorrhage. Regarding foetal outcome; meconium baby 32.5%, Intrapartum foetal distress 17.5%, preterm baby 10% while 37.5% were complication free. There was 2.5% of intrauterine foetal death, where pregnancy continued beyond 38 weeks. Thirteen new borns (32.5%) were admitted to neonatal intensive care unit. Conclusion: Cholestasis in pregnancy is high risk group with adverse perinatal outcomes.

show abstract

“…12 Bu düşüşün sebebi net açıklanamamakla birlikte; mevsimsel olan değişikliklere, selenyum eksikliğine ve hepatit C enfeksiyonuna bağlan-maktadır. 1 Avrupa'nın diğer kısımlarında; Amerika'da, Asya'da, Avustralya ve bazı Latin Amerikan ülkelerinde GİK insidansı artış göster-mektedir.…”

Section: Epi̇demi̇yoloji̇unclassified

“…Literatürde bildirilen çoğu in utero fetal ölüm vakaları 38. haftadan önce görülmektedir. 1,9,[78][79][80][81] Otuz sekizinci haftadan önce aktif yönetim ile doğumun gerçekleştirilmesi kabul görmektedir, fakat bazı obstetrik uzmanları bu görüşe karşı çıkmakta-dır. [82][83][84] "Royal College of Obstetricians and Gynecologists (RCOG)", GİK'da aktif tedaviyi destekleyen veya karşı çıkan bir kanıt olmadığı için rutin olarak uygulanan aktif tedaviyi desteklememekte, bunun yerine tedavinin bireyselleştirilmesini öner-mektedir.…”

Section: Gebeli̇ği̇n İntrahepati̇k Kolestazinda Hasta Yöneti̇mi̇unclassified

“…1 GİK günümüze kadar obstetrik kolestaz, gebelik sarılığı, gebeliğin idiyopatik sarı-lığı, gestasyonel veya obstetrik hepatoz gibi çeşitli isimlerle anılmıştır. 1 Hastalık, coğrafi konum ve etnik orijine göre %0,1-15,6 arasında değişen sık-lıkla görülmektedir. [2][3][4][5] Gebelikte viral hepatit tanısından sonra en sık görülen sarılık sebebidir.…”

unclassified

See 1 more Smart Citation